SOURCE: Wall Street Equity Research

Wall Street Equity Research

September 22, 2010 09:02 ET

Professional Research on Pfizer Inc. and Johnson & Johnson - A Brief Insight on the Challenges Affecting the Drug Makers' Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 22, 2010) - gives shareholders valuable insight on major drug manufacturers stocks Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). Sign up today at to receive free research reports on these equities.

The Drug Manufacturing sector faces some interesting challenges currently. One major challenge involves governments in the European Union controlling drug prices for their national health programs. Nearly all of the countries have fixed prices lower in an attempt to shore up their budget concerns. Also, European governments are requiring that drug manufacturers provide more proof of safety and effectiveness for the drugs before the governments buy them. is a specialized website where investors can have specific access to free reports major drug manufacturers industry; traders looking for analyst opinions on Pfizer Inc., Johnson & Johnson and other companies in this industry are welcomed to sign up for a free one year membership at

Another issue facing the sector is the current legal battle of controversial "pay-for-delay" settlements. While a judge recently ruled that the practice of brand named drug makers paying generic companies to defer introduction of generic drugs was legal, the case could make it to the U.S. Supreme court because of its national importance. Brand name drug prices typically fall 80% when generics are introduced. The Federal Trade Commission argues that this practice is anti-competitive and costs consumers billions of dollars every year. Visit us at to understand the catalysts and forces driving or affecting the major drug manufacturers industry in today's economic environment.

Elsewhere, companies like Pfizer Inc. are looking to mergers and acquisitions to help support growth in the face of huge patent fall-off during the next few years. Companies within the sector with weak pipelines are buying up smaller manufactures and biotech companies. Traders can get direct and free access to today's full report on Pfizer Inc. by signing up at

In news these past weeks is the recent talk by Johnson & Johnson to takeover Crucell for $2.3 billion so as to build a sturdy platform in the vaccine market. Traders can have complimentary access to today's complete research report on Johnson & Johnson by signing up at 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information